PD-L1 blockade therapeutic effect in Tau P301S (line PS19) mouse model of tauopathy
IBC-Ab002 Fc modifications for fast clearance are associated with advantageous safety profile
Alzheimer’s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis
Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy
IBC-Ab002, an anti-PD-L1 monoclonal antibody tailored for treating Alzheimer’s disease
PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease
Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer’s disease pathology.
Aging-induced type I interferon response at the choroid plexus negatively affects brain function.
